Multi oligosaccharide glycoconjugate bacterial meningitis vaccines

US6656472B1 · kind B1 · utility

Assignee

• Aventis Pasteur · CA

Inventors

• Pele Chong · King City, CA
• Alf Lindberg · Djursholm, SE
• Michel H. Klein · Willowdale, CA

Key dates

• Filing date: Dec 22, 2000
• Grant date: Dec 2, 2003
• Expiry date: Dec 22, 2020

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae which may be serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F), or Neisseria meningitidis, which may be serotype (A, B, C) W-135 or Y. Such oligosaccharide fragments may be sized from about 2 to about 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule. The multivalent molecules may be employed in vaccines or in the generation of antibodies for diagnostic applications.